Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Pertuzumab in combination with Trastuzumab in patients with Invasive Breast Carcinoma.

Statements

Source and description
Pertuzumab/Trastuzumab (Phesgo) Maintenance Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) for reimbursement as a treatment option for the maintenance treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment. The regime further states that patients should have already been treated with pertuzumab and trastuzumab in combination with DOCEtaxel, PACLItaxel, or vinorelbine.
Pertuzumab and Trastuzumab Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab for reimbursement as a treatment option for the maintenance treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in adult patients, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.